The disappointing results of anti-PD-1 and anti-PD-L1 ICIs as monotherapy in unselected patients with r/r DLBCL have led to a plethora of trials evaluating combination therapies in the r/r and upfront setting, in the hope of discovering synergistic effects. The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.